261 related articles for article (PubMed ID: 12490692)
1. Botanical medicines--the need for new regulations.
Marcus DM; Grollman AP
N Engl J Med; 2002 Dec; 347(25):2073-6. PubMed ID: 12490692
[No Abstract] [Full Text] [Related]
2. Botanical drugs: a future for herbal medicines.
Li W
J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224
[No Abstract] [Full Text] [Related]
3. Herbal medicine.
McGuffin M
N Engl J Med; 2003 Apr; 348(15):1498-501; author reply 1498-501. PubMed ID: 12691063
[No Abstract] [Full Text] [Related]
4. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
Buck ML
Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
[No Abstract] [Full Text] [Related]
5. Herbal medicine.
Wollschlaeger BA
N Engl J Med; 2003 Apr; 348(15):1498-501; author reply 1498-501. PubMed ID: 12691064
[No Abstract] [Full Text] [Related]
6. Herbal medicine in Europe--relaxing regulatory standards.
De Smet PA
N Engl J Med; 2005 Mar; 352(12):1176-8. PubMed ID: 15788494
[No Abstract] [Full Text] [Related]
7. Dosing botanical medicines.
Yarnell E
J Herb Pharmacother; 2005; 5(1):73-8. PubMed ID: 16093237
[No Abstract] [Full Text] [Related]
8. Herbal medicine.
Lipman MM
N Engl J Med; 2003 Apr; 348(15):1498-501; author reply 1498-501. PubMed ID: 12686712
[No Abstract] [Full Text] [Related]
9. Safety assessment of newly marketed herbal medicines--methodological approach (Ginkgo biloba example in Bulgaria).
Getov IN; Tzenova AT; Ristoff MS; Todorov TV; Petrova GI
J Herb Pharmacother; 2007; 7(3-4):239-57. PubMed ID: 18928145
[TBL] [Abstract][Full Text] [Related]
10. Prescribing herbal medications appropriately.
Ernst E
J Fam Pract; 2004 Dec; 53(12):985-8. PubMed ID: 15581442
[No Abstract] [Full Text] [Related]
11. Flight 483 now boarding.
Czap A
Altern Med Rev; 2010 Sep; 15(3):183-5. PubMed ID: 21155619
[No Abstract] [Full Text] [Related]
12. Scientific reporting of unscientific data--a case of Ginkgo biloba being miscredited.
Bruhn JG; ;
Phytomedicine; 2003 May; 10(4):358. PubMed ID: 12809368
[No Abstract] [Full Text] [Related]
13. "Black Box" warning labels and drug withdrawals.
Thomas JA
Toxicol Appl Pharmacol; 2002 Sep; 183(2):81. PubMed ID: 12387746
[No Abstract] [Full Text] [Related]
14. [Clinical phytotherapy: opportunities and problematics].
Firenzuoli F; Gori L; Neri D
Ann Ist Super Sanita; 2005; 41(1):27-33. PubMed ID: 16037646
[TBL] [Abstract][Full Text] [Related]
15. Essays in public health and preventive medicine. A call to Pharms: the need for tighter FDA regulation of the neutraceutical industry.
Dobrin J
Mt Sinai J Med; 2006 Mar; 73(2):565-6. PubMed ID: 16685816
[No Abstract] [Full Text] [Related]
16. FDA prohibits extralabel use of two drug classes.
J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
[No Abstract] [Full Text] [Related]
17. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
18. Herbal medicines in Malaysia.
Ang HH
Clin Pharmacol Ther; 2005 May; 77(5):451. PubMed ID: 15900291
[No Abstract] [Full Text] [Related]
19. Regulatory issues in pediatric psychopharmacology.
Laughren TP
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
[TBL] [Abstract][Full Text] [Related]
20. FDA perspectives on supplement use by patients on antithrombotic therapy.
Kim MJ
Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
[No Abstract] [Full Text] [Related]
[Next] [New Search]
